Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06944717 · ClinicalTrials.gov registry record · Phase 1
A Trial of a Norovirus G1.1 and G2.4 Vaccine Administered Orally to Healthy Participants Aged ≥ 18 Years and ≤ 80 Years Old
A Phase 1 study of Norovirus Infections, sponsored by Vaxart.
- Active
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT06944717: Active Phase 1 study of Norovirus Infections, sponsored by Vaxart.
NCT06944717 is a Phase 1 study of Norovirus Infections that is active but no longer recruiting, run by Vaxart. The registered enrollment target is 60 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06944717, a Phase 1 study of Norovirus Infections, is active but no longer recruiting, sponsored by Vaxart.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of this study is to determine the safety and immunogenicity of low and high dose regimens of a next generation norovirus bivalent G1.1 and G2.4 vaccine candidate in healthy participants.
Conditions Studied
Interventions
- BIOLOGICAL VXA-G1.1-NN
- BIOLOGICAL VXA-G2.4-NS
- BIOLOGICAL VXA G1.1 NN-T
- BIOLOGICAL VXA G2.4 NS-T
Study Locations (1)
Kansas
- Johnson County Clin Trials - JCCT - Lenexa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-03-03 |
| Est. Completion | 2026-05-01 |
| Phase | Phase 1 |
What the registry record for NCT06944717 still lists
NCT06944717 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.
The record links to 1 condition, with Norovirus Infections appearing as the primary indexed condition, and to 4 interventions - of which VXA-G1.1-NN is the first listed.
NCT06944717 reports a single indexed study location in Kansas.
Frequently Asked Questions
What is clinical trial NCT06944717 about?
NCT06944717 is a clinical study titled "A Trial of a Norovirus G1.1 and G2.4 Vaccine Administered Orally to Healthy Participants Aged ≥ 18 Years and ≤ 80 Years Old". The primary objective of this study is to determine the safety and immunogenicity of low and high dose regimens of a next generation norovirus bivalent G1.1 and G2.4 vaccine candidate in healthy participants.
What is the current status of trial NCT06944717?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2025-03-03. Estimated completion is 2026-05-01.
What conditions does trial NCT06944717 study?
This clinical trial studies the following conditions: Norovirus Infections.
What interventions are being tested in trial NCT06944717?
The interventions under investigation include: VXA-G1.1-NN (BIOLOGICAL), VXA-G2.4-NS (BIOLOGICAL), VXA G1.1 NN-T (BIOLOGICAL), VXA G2.4 NS-T (BIOLOGICAL).
Who is sponsoring clinical trial NCT06944717?
This trial is sponsored by Vaxart, which has 19 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06944717 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06944717's enrollment target sits among peer trials
60 831st of 2000 higher than 1,106 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI